Increased Dosage of MRA Improves BP and Urinary Albumin Excretion in Primary Aldosteronism With Suppressed Plasma Renin

PURPOSE: Excessive aldosterone secretion causes a high risk of cardio-cerebrovascular events. Mineralocorticoid receptor antagonist (MRA) is 1 of the treatment strategies for primary aldosteronism (PA). However, current MRA treatment is insufficient because MRA-treated patients with suppressed plasm...

Descripción completa

Detalles Bibliográficos
Autores principales: Saiki, Aya, Otsuki, Michio, Tamada, Daisuke, Kitamura, Tetsuhiro, Mukai, Kosuke, Yamamoto, Koichi, Shimomura, Iichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664755/
https://www.ncbi.nlm.nih.gov/pubmed/34909517
http://dx.doi.org/10.1210/jendso/bvab174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664755/
https://www.ncbi.nlm.nih.gov/pubmed/34909517
http://dx.doi.org/10.1210/jendso/bvab174

Ejemplares similares